Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013

Aref Al-Kali, D. Zblewski, James M Foran, Mrinal M Patnaik, Beth R. Larrabee, Naseema Gangat, Kebede Begna, Michelle A. Elliott, William Hogan, Ayalew Tefferi, Mark R Litzow, Ronald S. Go

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: To study the changes in overall outcome of patients with myelodysplastic syndromes (MDSs) after approval of several treatments. Patients and Methods: We identified 54,953 MDS cases in the National Cancer Data Base diagnosed from January 1, 2004, through December 31, 2013, using International Classification of Diseases for Oncology, 3rd edition, codes 9980, 9982-9983, 9985-9987, 9989, 9991-9992. Overall survival and different subgroups were studied over 3 periods of diagnoses (2004-2006, 2007-2009, and 2010-2013). Results: Median age at diagnosis was 76 years. The most common subtype was MDS-unclassifiable, which represented 55.6% of all cases. We found that males, older patients, patients with refractory anemia with excess blasts, Medicare insurance recipients, and those treated at nonacademic centers had the worse survival (P<.001). Overall survival did not improve over time, except in younger patients (<40 years old). Conclusion: In the past decade, overall outcome of MDS did not improve despite the advent of new therapies. More studies are needed to understand the impact of newly approved treatments on the outcome of patients with MDS.

Original languageEnglish (US)
Pages (from-to)1467-1474
Number of pages8
JournalMayo Clinic proceedings
Volume94
Issue number8
DOIs
StatePublished - Aug 1 2019

Fingerprint

Myelodysplastic Syndromes
Databases
Neoplasms
Survival
Refractory Anemia with Excess of Blasts
International Classification of Diseases
Medicare
Insurance
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Outcome of Myelodysplastic Syndromes Over Time in the United States : A National Cancer Data Base Study From 2004-2013. / Al-Kali, Aref; Zblewski, D.; Foran, James M; Patnaik, Mrinal M; Larrabee, Beth R.; Gangat, Naseema; Begna, Kebede; Elliott, Michelle A.; Hogan, William; Tefferi, Ayalew; Litzow, Mark R; Go, Ronald S.

In: Mayo Clinic proceedings, Vol. 94, No. 8, 01.08.2019, p. 1467-1474.

Research output: Contribution to journalArticle

@article{2cf0a4ac180e486288d067b6eae82135,
title = "Outcome of Myelodysplastic Syndromes Over Time in the United States: A National Cancer Data Base Study From 2004-2013",
abstract = "Objective: To study the changes in overall outcome of patients with myelodysplastic syndromes (MDSs) after approval of several treatments. Patients and Methods: We identified 54,953 MDS cases in the National Cancer Data Base diagnosed from January 1, 2004, through December 31, 2013, using International Classification of Diseases for Oncology, 3rd edition, codes 9980, 9982-9983, 9985-9987, 9989, 9991-9992. Overall survival and different subgroups were studied over 3 periods of diagnoses (2004-2006, 2007-2009, and 2010-2013). Results: Median age at diagnosis was 76 years. The most common subtype was MDS-unclassifiable, which represented 55.6{\%} of all cases. We found that males, older patients, patients with refractory anemia with excess blasts, Medicare insurance recipients, and those treated at nonacademic centers had the worse survival (P<.001). Overall survival did not improve over time, except in younger patients (<40 years old). Conclusion: In the past decade, overall outcome of MDS did not improve despite the advent of new therapies. More studies are needed to understand the impact of newly approved treatments on the outcome of patients with MDS.",
author = "Aref Al-Kali and D. Zblewski and Foran, {James M} and Patnaik, {Mrinal M} and Larrabee, {Beth R.} and Naseema Gangat and Kebede Begna and Elliott, {Michelle A.} and William Hogan and Ayalew Tefferi and Litzow, {Mark R} and Go, {Ronald S.}",
year = "2019",
month = "8",
day = "1",
doi = "10.1016/j.mayocp.2019.02.029",
language = "English (US)",
volume = "94",
pages = "1467--1474",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "8",

}

TY - JOUR

T1 - Outcome of Myelodysplastic Syndromes Over Time in the United States

T2 - A National Cancer Data Base Study From 2004-2013

AU - Al-Kali, Aref

AU - Zblewski, D.

AU - Foran, James M

AU - Patnaik, Mrinal M

AU - Larrabee, Beth R.

AU - Gangat, Naseema

AU - Begna, Kebede

AU - Elliott, Michelle A.

AU - Hogan, William

AU - Tefferi, Ayalew

AU - Litzow, Mark R

AU - Go, Ronald S.

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Objective: To study the changes in overall outcome of patients with myelodysplastic syndromes (MDSs) after approval of several treatments. Patients and Methods: We identified 54,953 MDS cases in the National Cancer Data Base diagnosed from January 1, 2004, through December 31, 2013, using International Classification of Diseases for Oncology, 3rd edition, codes 9980, 9982-9983, 9985-9987, 9989, 9991-9992. Overall survival and different subgroups were studied over 3 periods of diagnoses (2004-2006, 2007-2009, and 2010-2013). Results: Median age at diagnosis was 76 years. The most common subtype was MDS-unclassifiable, which represented 55.6% of all cases. We found that males, older patients, patients with refractory anemia with excess blasts, Medicare insurance recipients, and those treated at nonacademic centers had the worse survival (P<.001). Overall survival did not improve over time, except in younger patients (<40 years old). Conclusion: In the past decade, overall outcome of MDS did not improve despite the advent of new therapies. More studies are needed to understand the impact of newly approved treatments on the outcome of patients with MDS.

AB - Objective: To study the changes in overall outcome of patients with myelodysplastic syndromes (MDSs) after approval of several treatments. Patients and Methods: We identified 54,953 MDS cases in the National Cancer Data Base diagnosed from January 1, 2004, through December 31, 2013, using International Classification of Diseases for Oncology, 3rd edition, codes 9980, 9982-9983, 9985-9987, 9989, 9991-9992. Overall survival and different subgroups were studied over 3 periods of diagnoses (2004-2006, 2007-2009, and 2010-2013). Results: Median age at diagnosis was 76 years. The most common subtype was MDS-unclassifiable, which represented 55.6% of all cases. We found that males, older patients, patients with refractory anemia with excess blasts, Medicare insurance recipients, and those treated at nonacademic centers had the worse survival (P<.001). Overall survival did not improve over time, except in younger patients (<40 years old). Conclusion: In the past decade, overall outcome of MDS did not improve despite the advent of new therapies. More studies are needed to understand the impact of newly approved treatments on the outcome of patients with MDS.

UR - http://www.scopus.com/inward/record.url?scp=85069881096&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069881096&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2019.02.029

DO - 10.1016/j.mayocp.2019.02.029

M3 - Article

C2 - 31378228

AN - SCOPUS:85069881096

VL - 94

SP - 1467

EP - 1474

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 8

ER -